Timing of Radiotherapy (RT) After Radical Prostatectomy (RP): Final Results of RADICALS RT Randomised Controlled Trial [NCT00541047]

ARTO (NCT03449719), randomized phase II trial testing stereotactic body radiotherapy and Abiraterone Acetate in Oligometastatic castrate-resistant prostate cancer patients

Avelumab (AVE) combined with cetuximab (CET) and irinotecan (IRI) for the treatment of refractory microsatellite stable (MSS) metastatic colorectal cancer (mCRC) – The AVETUXIRI Phase II study (NCT03608046).

Phase 1b/2 Open-label Study (NCT04073615) to Evaluate the Safety, Tolerability, and Efficacy of Rivoceranib plus Trifluridine/Tipiracil in Patients with Previously Treated Metastatic Colorectal Cancer

Neoadjuvant PD-1 inhibitor combined with Nab-paclitaxel and cisplatin in resectable locally advanced head and neck squamous cell carcinoma (NCT05522985): A randomized, controlled, open label, phase II clinical trial

Tumor-restricted delivery of an immune-therapeutic payload by modified macrophages for the treatment of Glioblastoma: the TEM-GBM STUDY (NCT03866109)

Final top-line results of the BGBC008 phase 2, multicenter study of bemcentinib and pembrolizumab (bem+pembro) in 2nd line (2L) advanced non-squamous (NS) non-small cell lung cancer (NSCLC) (NCT03184571)

Efficacy study of osimertinib in treatment-naïve patients with EGFR mutant Non-Small Cell Lung Cancer (NSCLC) according to TP53 mutational status (TEMPLE-2/NCT05785208).

Blood-borne Assessment of Stromal activation in esophageAL adenocarcinoma to guide tocilizumab Therapy: a randomized phase II proof-of-concept study (NCT04554771)

PSMA guided approach for bIoCHEmical relapse after prostatectomy-PSICHE trial (NCT05022914)

Results from a Phase I/II trial of tinostamustine monotherapy in advanced solid tumours (NCT03345485): safety and efficacy in a subset of patients (pts) with soft tissue sarcoma (STS)